Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 16;15(1):96.
doi: 10.1186/s13048-022-01029-6.

Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer

Xin-Ru Li  1   2 , Xing-Han Cheng  2 , Guo-Nan Zhang  3   4 , Xiao-Xin Wang  2   5   6 , Jian-Ming Huang  2   5
Affiliations
Review

Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer

Xin-Ru Li et al. J Ovarian Res. .

Abstract

Pegylated liposomal doxorubicin (PLD) is a nano-doxorubicin anticancer agent. It was used as early as 2014 to treat ovarian and breast cancer, multiple myeloma and Kaposi's sarcoma. The 2018 National Comprehensive Cancer Network guidelines listed PLD as first-line chemotherapy for ovarian cancer. PLD has significant anticancer efficacy and good tolerance. Although PLD significantly reduces the cardiotoxicity of conventional doxorubicin, its cumulative-dose cardiotoxicity remains a clinical concern. This study summarizes the high-risk factors for PLD-induced cardiotoxicity, clinical dose thresholds, and cardiac function testing modalities. For patients with advanced, refractory, and recurrent malignant tumors, the use of PLD is still one of the most effective strategies in the absence of evidence of high risk such as cardiac dysfunction, and the lifetime treatment dose should be unlimited. Of course, they should also be comprehensively evaluated in combination with the high-risk factors of the patients themselves and indicators of cardiac function. This review can help guide better clinical use of PLD.

Keywords: Cardiac function test; Cardiotoxicity; High-risk factors; Ovarian cancer; Pegylated liposomal doxorubicin.

PubMed Disclaimer

Conflict of interest statement

All the authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Chemical structure of doxorubicin
Fig. 2
Fig. 2
Chemical structure of pegylated liposomal doxorubicin
See this image and copyright information in PMC

References

    1. Cagel M, Grotz E, Bernabeu E, Moretton MA, Chiappetta DA. Doxorubicin: nanotechnological overviews from bench to bedside. Drug Discovery Today. 2017;22(2):270–281. doi: 10.1016/j.drudis.2016.11.005. - DOI - PubMed
    1. MM. AH Salem HSE, Ghanem E, Abdel-Daim. Mesenchymal Stem Cell Therapy for Doxorubicin-Induced Cardiomyopathy: Potential Mechanisms, Governing Factors, and Implications of the Heart Stem Cell Debate. Front Pharmacol. 2019;10:635. - PMC - PubMed
    1. Wolfram J, Ferrari M. Clinical cancer nanomedicine. Nano Today. 2019;25:85–98. doi: 10.1016/j.nantod.2019.02.005. - DOI - PMC - PubMed
    1. J. WhZheng M. Gao J, Wang J, Zhang Q, Fawcett JP, He Y, Gu Uptake and release profiles of PEGylated liposomal doxorubicin nanoparticles: A comprehensive picture based on separate determination of encapsulated and total drug concentrations in tissues of tumor- Talanta. 2020;1(208):120358. - PubMed
    1. DOXIL Label. Food and Drug Administration. 2016;

MeSH terms